Gad Thomas's Form 4 filing
Y-mAbs Therapeutics, Inc. (YMAB) · filed Aug 17, 2021
- Accession no.
- 0001104659-21-107093
- Filed
- Aug 17, 2021
- Trade date
- Aug 13-17, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $851.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gad ThomasCIK 0001753224 | Director, Officer (See remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2021 | Common Stock | SSaleDisposed | −1,110 | $31.01F1 | −$34,421.1 | 1,582,817 | Indirect | |
| Aug 16, 2021 | Common Stock | SSaleDisposed | −4,000 | $29.14F4 | −$116,560 | 1,578,817 | Indirect | |
| Aug 16, 2021 | Common Stock | SSaleDisposed | −22,111 | $29.33F5 | −$648,515.63 | 1,556,706 | Indirect | |
| Aug 17, 2021 | Common Stock | SSaleDisposed | −1,779 | $28.96F6 | −$51,519.84 | 1,554,927 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This transaction was executed in multiple trades at prices ranging from $31.00 to $31.06. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $28.50 to $29.63. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $29.00 to $29.68. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $28.42 to $29.72. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
Chairman, President and Head of Business Development & Strategy